PRIMARY BREAST CANCER THERAPY GROUP-NSABP

这项研究提案旨在使新英格兰医学中心能够 继续参与Priamry乳腺癌治疗小组--NSABP。 NSABP的总体具体目标是提高无病存活率 一期可手术乳房和结直肠癌患者的生存率 癌症。 塔夫茨大学/新英格兰医学中心网络一直是NSABP 自1971年6月以来一直是会员。目前，86名患者正在接受随访 长期辅助方案，每年新患者应收率为28% 每年的病人数量。我们希望将我们的应计利率提高到大约 每年38名患者，基于NSABP开放的乳房方案 乳房节段性切除术的病人，对外科医生的教育 关于转介结节阴性和导管内乳腺癌患者 最近还收购了两个强大的附属公司基础。这些条目的条目 患者将通过实现更快速有效的NSABP目标 对目前的治疗方案进行评估，并将为 未来研究的设计。 新英格兰医疗中心项目的独特之处 NSABP的总体成功包括：1)多学科乳房 健康中心2)癌基因领域的基础研究，3) 雌激素受体检测的研究进展及临床应用 IL-2和淋巴因子等生物反应调节剂的作用 雌激素/三苯氧胺激活的细胞毒作用和Tuftsin的作用机制 肿瘤细胞的生长。

This research proposal is designed to enable New England Medical Center to continue participation in the priamry Breast Cancer Therapy Group--NSABP. The overall specific aim of the NSABP is to improve disease free survival and survival in patients with primary operable breast and colo-rectal cancer. The Tufts University/New England Medical Center network has been an NSABP member since June 1971. Currently, 86 patients are being followed on long-term adjuvant protocols, at an annual new patient accrual rate of 28 patients per year. We expect to increase our accrual rate to approximately 38 patients per year based on the opening of NSABP breast protocols to patients who have undergone segmental mastectomy, education of surgeons regarding referral of node-negative and intraductal breast cancer patients and recent acquisition of two strong affiliate bases. The entry of these patients will enhance NSABP goals by enabling a more rapid and effective evaluation of current therapeutic regimes and will provide information for the design of future studies. Unique features of the New England Medical Center program which contribute to the overall success of NSABP include: 1) the multidisciplinary Breast Health Center 2) basic research conducted in the areas of oncogenes, 3) estrogen receptor assay research development and 4) clinical application of the role of biological response modifiers such as IL-2 and lymphokine activated cytotoxity and tuftsin and mechanisms of estrogen/tamoxofin on growth of tumor cells.